Seven known dibenzocyclooctadiene lignans,tigloylgomisin P(1), angeloylgomisin P(2),gomisin A(3),Schizandrin(4),angeloylgomisin H(5),gomisin B(6) and R(+)-gomisin M_1(7)were isolated from Kadsura heteroclita.The confo...Seven known dibenzocyclooctadiene lignans,tigloylgomisin P(1), angeloylgomisin P(2),gomisin A(3),Schizandrin(4),angeloylgomisin H(5),gomisin B(6) and R(+)-gomisin M_1(7)were isolated from Kadsura heteroclita.The conformation of tiglolylgomisin P(1)was established by 2D NMR techniques.Using[~3H]platelet activating factor(PAF)binding to human platelet membrane assay,(1),(2)and(7)showed PAF receptor antagonistic activities.展开更多
AIM： To evaluate the changes in hepatic platelet activating factor （PAF） and its receptors and their effect on portal pressure of cirrhotic rats induced by CCh. METHODS： A model of liver cirrhosis was replicated i...AIM： To evaluate the changes in hepatic platelet activating factor （PAF） and its receptors and their effect on portal pressure of cirrhotic rats induced by CCh. METHODS： A model of liver cirrhosis was replicated in rats by intra-peritoneal injection of CCh for 8 wk. We determined the effect of hepatic PAF and its receptor level on portal and arterial pressure by EIA, saturation binding and RT-PCR technique. RESULTS： Compared to control rats, cirrhotic rats had higher hepatic PAF levels and output as well as higher plasma PAF levels （P〈0.01, P〈0.01, P〈0.05, respectively）. Both hepatic PAF receptor mRNA levels and PAF binding were nearly 3-fold greater in cirrhotic rats （P〈0.01）. Portal injection of PAF （1 g/kg WT） increased the portal pressure by 22% and 33% in control and cirrhotic rats, respectively. In contrast, the arterial pressure was decreased in the both groups （54% in control rats and 42% in cirrhotic rats）. Injection of the PAF antagonist BN52021 （5 mg/kg WT） decreased the portal pressure by 16% in cirrhotic rats but had no effect in the control rats. CONCLUSION： The upregulation of the PAF system contributes to hepatic hemodynamic and metabolic abnormalities in drrhosis, and the increased release of PAF into the circulation has impacts on the systemic hemodynamics.展开更多
基金This project was supported by National Natural Science Foundation of China.
文摘Seven known dibenzocyclooctadiene lignans,tigloylgomisin P(1), angeloylgomisin P(2),gomisin A(3),Schizandrin(4),angeloylgomisin H(5),gomisin B(6) and R(+)-gomisin M_1(7)were isolated from Kadsura heteroclita.The conformation of tiglolylgomisin P(1)was established by 2D NMR techniques.Using[~3H]platelet activating factor(PAF)binding to human platelet membrane assay,(1),(2)and(7)showed PAF receptor antagonistic activities.
基金Supported by the Key Scientific and Technological Research Foundation of the National 863 Program,No.2003AA208106Medical Outstandard Foundation of Army,No.04J020
文摘AIM： To evaluate the changes in hepatic platelet activating factor （PAF） and its receptors and their effect on portal pressure of cirrhotic rats induced by CCh. METHODS： A model of liver cirrhosis was replicated in rats by intra-peritoneal injection of CCh for 8 wk. We determined the effect of hepatic PAF and its receptor level on portal and arterial pressure by EIA, saturation binding and RT-PCR technique. RESULTS： Compared to control rats, cirrhotic rats had higher hepatic PAF levels and output as well as higher plasma PAF levels （P〈0.01, P〈0.01, P〈0.05, respectively）. Both hepatic PAF receptor mRNA levels and PAF binding were nearly 3-fold greater in cirrhotic rats （P〈0.01）. Portal injection of PAF （1 g/kg WT） increased the portal pressure by 22% and 33% in control and cirrhotic rats, respectively. In contrast, the arterial pressure was decreased in the both groups （54% in control rats and 42% in cirrhotic rats）. Injection of the PAF antagonist BN52021 （5 mg/kg WT） decreased the portal pressure by 16% in cirrhotic rats but had no effect in the control rats. CONCLUSION： The upregulation of the PAF system contributes to hepatic hemodynamic and metabolic abnormalities in drrhosis, and the increased release of PAF into the circulation has impacts on the systemic hemodynamics.
